Publish in this journal
Journal Information
Vol. 6. Issue 1.
Pages 56-57 (January - February 2010)
Download PDF
More article options
Vol. 6. Issue 1.
Pages 56-57 (January - February 2010)
DOI: 10.1016/S2173-5743(10)70011-3
Full text access
Response to rituximab in a patient with Wegener's granulomatosis refractory to conventional therapies
Respuesta a rituximab en un paciente con granulomatosis de Wegener refractaria a terapia convencional
Inmaculada Macías Fernández
Sección de Reumatología, Hospital Universitario Puerta del Mar, Cádiz, Spain
Article information
Download PDF

Male patient with a diagnosis of Wegener's granulomatosis associated to anti-proteinase 3 antibodies that improved initially to treatment with high dose glucocorticoids and cyclophosphamide but who relapsed, with a poor response to glucocorticoid treatment, cyclophosphamide, methotrexate and azathioprine. The patient received treatment with rituximab in 4 doses with clinical and radiographic improvement.

Wegener's granulomatosis
Biological therapies

Se presenta el caso de un paciente con granulomatosis de Wegener asociada a anticuerpos antiproteinasa 3 que tuvo mejoría inicial con dosis altas de glucocorticoides y ciclofosfamida, pero que posteriormente a una recaída no respondió a los mismos medicamentos, ni a metotrexate ni a zatioprina. Por tal motivo, recibió tratamiento con rituximab en 4 dosis, además de glucocorticoides, obteniendo mejoría del cuadro tanto clínica como radiográficamente.

Palabras clave:
Granulomatosis de Wegener
Terapias biológicas
Full text is only aviable in PDF
P. Seo, J.H. Stone.
Update on medium and small vessel vasculitides.
Arthritis Care Res, 53 (2005), pp. 93-99
L. Guillevin, J.F. Cordier, F. Lhote, P. Cohen, B. Jarrousse, I. Royer, et al.
A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis.
R.W. Lee, D.P. D’Cruz.
Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis.
Drugs, 68 (2008), pp. 747-770
K.R. Chen, J.A. Carlson.
Clinical approach to cutaneous vasculitis.
Am J Clin Dermatol, 9 (2008), pp. 71-92
K.A. Keogh, S.R. Ytterberg, F.C. Fervenza, K.A. Carlson, D.R. Schroeder, U. Specks.
Rituximab for refractory Wegener's granulomatosis: report of a prospective, openlabel pilot trial.
Am J Respir Crit Care Med, 173 (2006), pp. 180-187
R. Stasi, E. Stipa, G. Del Poeta, S. Amadori, A.C. Newland, D. Provan.
Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
Rheumatology, 45 (2006), pp. 1432-1436
D. Sánchez Cano, J.L. Callejas Rubio, N. Ortego Centeno.
Effect of rituximab on refractory Wegener granulomatosis with predominant granulomatous disease.
J Clin Rheumatol, 14 (2008), pp. 92-93
D. Wayne.
What place for the new biologics in the treatment of necrotising vasculitides.
Clin Exp Rheumatol, 24 (2006), pp. S1-S5
P.M. Aries, B. Hellmich, J. Voswinkel, M. Both, B. Nölle, K. Holl-Ulrich, et al.
Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations.
Ann Rheum Dis, 65 (2006), pp. 853-858
B. Brihaye, A. Aouba, C. Pagnoux, P. Cohen, F. Lacassin, L. Guillevin.
Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients.
Clin Exp Rheumatol, 25 (2007), pp. 23-27
R. Jones, C. Savage, C.A. Peh.
Rituximab: a novel remission induction agent in ANCA associated vasculitis. The design of an international, randomised trial (RITUXVAS).
J Am Soc Nephrol, 18 (2007), pp. 972A
Copyright © 2010. Sociedad Española de Reumatología and Colegio Mexicano de Reumatología
Reumatología Clínica (English Edition)

Subscribe to our newsletter

Article options
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.